Palliative management of malignant bowel obstruction

International Journal of Gynecological Cancer

Volumn 12, Issue 2, 2002, Pages 135-143

  Ripamonti, Carla ^a   Bruera, Eduardo ^b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AUTOPSY; CANCER STAGING; CANCER THERAPY; CAUSE OF DEATH; HUMAN; INTESTINE OBSTRUCTION; OVARY CANCER; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SMALL INTESTINE OBSTRUCTION;

ANALGESICS, OPIOID; DRAINAGE; FEMALE; GASTROINTESTINAL AGENTS; GENITAL NEOPLASMS, FEMALE; HUMANS; INTESTINAL OBSTRUCTION; PALLIATIVE CARE; PARENTERAL NUTRITION, TOTAL; PROGNOSIS; STENTS; TERMINAL CARE;

EID: 0036245071     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01103.x     Document Type: Review

References (85)

1. The management of ovarian-cancer-caused bowel obstruction
2. Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy
3. Intestinal operations in patients with ovarian carcinoma
4. Bowel complications in the management of ovarian cancer
5. Bowel obstruction in ovarian carcinoma: A retrospective study and review of the literature
6. Clinicalpractice recommendations for the management of bowel obstruction in patients with end-stage cancer
7. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer
8. Surgical management of bowel obstruction in advanced ovarian carcinoma
9. Mechanical intestinal obstruction in patients with gynecologic disease: A review of 368 patients
10. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival
11. Palliative surgery for intestinal obstruction in advanced ovarian cancer
12. Treatment of bowel obstruction after operation for colorectal carcinoma
13. Intestinal obstruction in patients with gynaecological malignancies
14. The role of somatostatin and octreotide in bowel obstruction: Preclinical and clinical results
15. Survival after ovarian cancer-induced intestinal obstruction
16. Chronic intestinal obstruction: Value of percutaneous gastrostomy tube placement
17. Surgical treatment of gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin
18. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer
19. Management of intestinal obstruction in advanced ovarian cancer: An analysis of 57 cases
20. Survival following intestinal obstruction in ovarian cancer
21. Small bowel obstruction in patients with a prior history of cancer
22. Intestinal obstruction in patients with widespread intra-abdominal malignancy
23. Management of bowel obstruction in patients with abdominal cancer
24. Bowel obstruction in patients with ovarian carcinoma: Analysis of prognostic factors
25. Intestinal obstruction in cancer patients: An assessment of risk factors and outcome
26. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer
27. Surgical palliation of small bowel obstruction due to metastatic carcinoma
28. Is laparotomy for small bowel obstruction justified in patients with previously treated malignancy?
29. Results of surgery for obstructing carcinomatosis of gastrointestinal of gastrointestinal, pancreatic, or biliary origin
30. Surgical management of intestinal obstruction in the late course of malignant disease
31. Bowel obstruction in patients with ovarian cancer: A search for prognostic factors
32. High mortality after abdominal operation in patients with large-volume malignant ascites
33. Small intestinal obstruction from peritoneal carcinomatosis
34. Management of bowel obstruction in patients with advanced ovarian cancer
35. Pour une meilleure qualité de vie en fin de vie: Nutrition et hydratation
36. Surgical management of intestinal obstruction in ovarian cancer II. Analysis of factors associated with complications and survival
37. Bowel obstruction in cancer patients: Performance status as a predictor of survival
38. Self-expanding metal stents in the management of colorectal carcinoma: A preliminary report
39. The role of metallic stents in malignant duodenal obstruction
40. Malignant gastric and duodenal stenosis: Palliation by peroral implantation of a self-expanding metallic stent
41. Upper gastrointestinal tract malignant obstruction: Initial results of palliation with a flexible covered stent
42. Relief of malignant duodenal obstruction by percutaneous insertion of a metal stent
43. Duodenal obstruction secondary to a metastasis from an adenocarcinoma of the cecum: A case report
44. Percutaneous endoscopic gastrostomy: The end of the line for nasogastric feeding?
45. Home support of patients with end-stage malignant bowel obstruction using hydration and venting gastrostomy
46. Palliation of small bowel obstruction by percutaneous gastrostomy in patients with progressive ovarian carcinoma
47. Percutaneous endoscopic gastrostomy: A two year experience
48. Percutaneous endoscopic gastrostomy for decompression of the stomach and small bowel
49. Percutaneous gastrostomy for decompression in patients with advanced gynecologic malignancirs
50. Palliative treatment of upper intestinal obstruction by gynecological malignancy: The usefulness of percutaneous endoscopic gastrostomy
51. Gastroduodenal decompression and simultaneous nasoenteral nutrition: 'Extracorporeal gstrojejunostomy'
52. Medical management of intestinal obstruction in patients with advanced malignant disease: A clinical and pathological study
53. The management of inoperable gastrointestinal obstruction in terminal cancer patients
54. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction
55. Glycopyrrolate: A useful drug in the palliation of mechanical bowel obstruction
56. Role of octreotide, scopolamine butylbromide and hydration in symptom control of patients with inoperable bowel obstruction having a nasogastric tube: A prospective, randomized clinical trial
57. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction
58. Direct proabsorptive effect of octreotide on ionic transport in the small intestine
59. The physiology of somatostatin and its synthetic analogue, octreotide
60. Octreotide, a potent new non-opiate analgesic for intrathecal infusion
61. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin
62. In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum
63. The role of octreotide in palliative care
64. Gastrointestinal peptide hormones during postoperative ileus: Effect of octreotide
65. Improvement in survival of mice with proximal small bowel obstruction treated with octreotide
66. Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: Experimental protocol
67. The effect of somatostatin on experimental intestinal obstruction
68. Effects of octreotide on healing of intestinal anastomosis following small bowel obstruction in rats
69. Inflammation as a major cause of fluid losses in small-bowel obstruction
70. Does vasoactive intestinal polypeptide mediate the pathophysiology of bowel obstruction?
71. Plasma vasoactive intestinal polypeptide (VIP) levels and intestinal ischemia
72. Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction
73. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients
74. Octreotide may prevent definitive intestinal obstruction
75. Somatostatin as adjuvant therapy in the management of obstructive ileus
76. Octreotide in the management of inoperable bowel obstruction in terminal cancer patients
77. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction
78. Control of emesis in bowel obstruction in terminally ill patients
79. Octreotide in terminal malignant obstruction of the gastrointestinal tract
80. Octreotide in the management of bowel obstruction in terminal ovarian cancer
81. Symptom control in terminally ill patients with malignant bowel obstruction (MBO)
82. Outcome of cancer patients receiving home parenteral nutrition
83. Guideline on artificial nutrition versus hydration in terminal cancer patients
84. The use of hypodermoclisis for rehydration in terminally ill cancer patients